Logo image
Ligand-dependent Corepressor Acts as a Novel Androgen Receptor Corepressor, Inhibits Prostate Cancer Growth, and Is Functionally Inactivated by the Src Protein Kinase
Journal article   Peer reviewed

Ligand-dependent Corepressor Acts as a Novel Androgen Receptor Corepressor, Inhibits Prostate Cancer Growth, and Is Functionally Inactivated by the Src Protein Kinase

Mohammad Asim, Bilal Bin Hafeez, Imtiaz Ahmad Siddiqui, Claudia Gerlach, Michaela Patz, Hasan Mukhtar and Aria Baniahmad
The Journal of biological chemistry, Vol.286(43), pp.37108-37117
28/10/2011
PMID: 21856747

Abstract

Androgen Androgen Receptor Corepressor Transcription Prostate Cancer Src
The activated androgen receptor (AR) promotes prostate cancer (PCa) growth. AR antagonists repress the AR by recruitment of corepressors. Not much is known about the inactivation of AR by corepressors in the presence of agonists (androgens). Here we show that the corepressor LCoR acts as an androgen-dependent corepressor that represses human PCa growth in vivo. In line with this, progressive decrease of ligand-dependent corepressor expression was observed in the PCa TRAMP mouse model with increasing age. LCoR interacts with AR and is recruited to chromatin in an androgen-induced manner. Unexpectedly, the LXXLL motif of LCoR is dispensable for interaction with the AR. Rather, the data indicate that LCoR interacts with the AR DNA binding domain on DNA. Interestingly, the interaction of LCoR with AR is inhibited by signaling pathways that are associated with androgen-independent PCa. Here we also show that the Src kinase inactivates the corepressive function of LCoR. Interfering with endogenous Src function by a dominant negative Src mutant, the growth inhibitory activity of LCoR is enhanced in vivo in a xenograft mouse model system. Thus, our studies indicate a role of LCoR as an AR corepressor and a tumor suppressor. Further, the decreased expression or inactivation of LCoR is as an important step toward PCa carcinogenesis in vivo. Background: Prostate cancer (PCa) growth is promoted by the androgen receptor (AR). Castration-resistant PCa is associated with activated signaling pathways. Results: LCoR represses human PCa growth in vivo. Src kinase inactivates the corepressive function of LCoR in vivo. Conclusion: LCoR, a novel corepressor for AR, inhibits PCa cell growth in vivo. LCoR is inactivated by Src kinase in castration-resistant PCa. Significance: As a ligand-dependent CoR, LCoR is able to inhibit AR activity in the presence of agonists in comparison to SMRT, Alien, or NCoR and thus could offer new therapies without applying antagonists, which result in androgen-independent growth. For this, the target could be the here-described Src pathway.
url
https://doi.org/10.1074/jbc.M111.292771View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image

Usage Policy